Literature DB >> 7599915

Comparison of 2- and 3-compartment models for the Bayesian estimation of methotrexate pharmacokinetics.

C Sabot1, J Debord, B Roullet, P Marquet, L Merle, G Lachatre.   

Abstract

Moderate and high-dose methotrexate was given by a 4-h infusion to 10 patients. The pharmacokinetics of methotrexate, determined by fluorescence polarization immuno-assay, was successively described by a 2- and a 3-compartment open model with elimination from the central compartment. Population pharmacokinetic parameters were obtained by non-linear regression from 8 data points for each course and were subsequently used to fit the same data by the Bayesian estimation method. According to Akaike's information criterion, the 3-compartment model was found statistically superior in 7 patients out of 10. Using this model clearance was well predicted (+/- 5%) by the Bayesian method with only 2 points taken at the end of the infusion and 24 h after. The prediction was less good for the steady-state volume of distribution (+/- 18%) and the half-lives (+/- 20-30%). This procedure enables a good estimation of individual pharmacokinetic parameters for methotrexate, specially with clearance, at minimal cost and minimal disturbance for the patient.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7599915

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther        ISSN: 0946-1965            Impact factor:   1.366


  9 in total

1.  Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia.

Authors:  Dolores Aumente; Dolores Santos Buelga; John C Lukas; Pedro Gomez; Antonio Torres; Maria José García
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 2.  Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology.

Authors:  Anthe S Zandvliet; Jan H M Schellens; Jos H Beijnen; Alwin D R Huitema
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

3.  Bayesian estimation of methotrexate pharmacokinetic parameters and area under the curve in children and young adults with localised osteosarcoma.

Authors:  Annick Rousseau; Christophe Sabot; Nicole Delepine; Gerard Delepine; Jean Debord; Gerard Lachâtre; Pierre Marquet
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

4.  Maximum a posteriori Bayesian estimation of oral cyclosporin pharmacokinetics in patients with stable renal transplants.

Authors:  Frédéric Leger; Jean Debord; Yann Le Meur; Annick Rousseau; Mathias Büchler; Gérard Lachâtre; Gilles Paintaud; Pierre Marquet
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 5.  Adaptive control methods for the dose individualisation of anticancer agents.

Authors:  A Rousseau; P Marquet; J Debord; C Sabot; G Lachâtre
Journal:  Clin Pharmacokinet       Date:  2000-04       Impact factor: 6.447

Review 6.  Nanotechnology and artificial intelligence to enable sustainable and precision agriculture.

Authors:  Peng Zhang; Zhiling Guo; Sami Ullah; Georgia Melagraki; Antreas Afantitis; Iseult Lynch
Journal:  Nat Plants       Date:  2021-06-24       Impact factor: 15.793

Review 7.  Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis.

Authors:  B Bannwarth; F Péhourcq; T Schaeverbeke; J Dehais
Journal:  Clin Pharmacokinet       Date:  1996-03       Impact factor: 6.447

Review 8.  Role of population pharmacokinetics in drug development. A pharmaceutical industry perspective.

Authors:  E Samara; R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-04       Impact factor: 6.447

9.  The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis.

Authors:  C Godfrey; K Sweeney; K Miller; R Hamilton; J Kremer
Journal:  Br J Clin Pharmacol       Date:  1998-10       Impact factor: 4.335

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.